Which stock is cheaper: MANKIND or SUNPHARMA?

Based on Price to Earnings, MANKIND trades at a P/E of 50.6 while SUNPHARMA trades at a P/E of 36.1.

Does MANKIND or SUNPHARMA have higher ROCE?

MANKIND generates an ROCE of 15.6% compared to SUNPHARMA's ROCE of 22.1%.

What is the market cap difference between MANKIND PHARMA LIMITED and SUN PHARMACEUTICAL IND L?

MANKIND PHARMA LIMITED (MANKIND) has a market cap of ₹94,174 Cr compared to SUN PHARMACEUTICAL IND L (SUNPHARMA) with ₹4,41,478 Cr.

MANKIND PHARMA LIMITED vs SUN PHARMACEUTICAL IND L (MANKIND vs SUNPHARMA) — Head-to-Head Comparison

MANKINDHealthcare

MANKIND PHARMA LIMITED

Leads (3/5)

₹2,492.80+0.95%

Market Cap: ₹94,174 Cr

View Full MANKIND Financials

SUNPHARMAHealthcare

SUN PHARMACEUTICAL IND L

₹1,777.70+0.95%

Market Cap: ₹4,41,478 Cr

View Full SUNPHARMA Financials

Key Comparison Takeaways

Automated quantitative breakdown of fundamental strengths between MANKIND and SUNPHARMA.

Attractive ValuationSUNPHARMA (P/E 36.1)Trades at lower Price-to-Earnings

Capital EfficiencySUNPHARMA (ROCE 22.1%)Superior operating return on capital

Balance Sheet SafetyMANKINDLower debt-to-equity ratio

Shareholder YieldMANKIND (8.00%)Higher annual dividend yield

Fundamental Metrics Head-to-Head

Green highlight indicates the stronger metric

Financial Metric	MANKIND	SUNPHARMA
Valuation Multiples
Market Capitalization	₹94,174 Cr	₹4,41,478 Cr
Price to Earnings (P/E)	50.58	36.07
Price to Book (P/B)	5.74	19.73
Profitability & Capital Efficiency
Return on Capital Employed (ROCE)	15.58%	22.11%
Return on Equity (ROE)	13.97%	12.96%
Operating Profit Margin (OPM)	21.31%	27.39%
Net Profit Margin (NPM)	17.59%	12.40%
Balance Sheet & Solvency
Debt to Equity Ratio	0.34	0.61
Dividend Yield	8.00%	4.84%
Historical Growth
3-Year Sales Growth (CAGR)	14.17%	11.41%
Latest Quarter Financial Results
Quarterly Revenue (30 Jun 2026)	₹4,031 Cr	₹15,184 Cr
Quarterly Net Profit	₹568 Cr	₹2,895 Cr

Shareholding Pattern Comparison

MANKIND Ownership (Nov 2026)

Promoters:75.28%

Foreign Institutions (FII):74.94%

Domestic Institutions (DII):0.00%

Public & Others:0.00%

SUNPHARMA Ownership (Nov 2026)

Promoters:55.61%

Foreign Institutions (FII):66.70%

Domestic Institutions (DII):0.00%

Public & Others:0.00%

Related Comparisons in Healthcare

SUNPHARMA vs CIPLA

Sun Pharmaceutical Industries vs Cipla Limited

DIVISLAB vs SUNPHARMA

Divi's Laboratories vs Sun Pharmaceutical Industries

DRREDDY vs SUNPHARMA

Dr. Reddy's Laboratories vs Sun Pharmaceutical Industries

LUPIN vs SUNPHARMA

Lupin Limited vs Sun Pharmaceutical Industries

MANKIND vs CIPLA

Mankind Pharma vs Cipla Limited

APOLLOHOSP vs MAXHEALTH

Apollo Hospitals Enterprise vs Max Healthcare Institute

Financial Metric	MANKIND	SUNPHARMA
Valuation Multiples
Market Capitalization	₹94,174 Cr	₹4,41,478 Cr
Price to Earnings (P/E)	50.58	36.07
Price to Book (P/B)	5.74	19.73
Profitability & Capital Efficiency
Return on Capital Employed (ROCE)	15.58%	22.11%
Return on Equity (ROE)	13.97%	12.96%
Operating Profit Margin (OPM)	21.31%	27.39%
Net Profit Margin (NPM)	17.59%	12.40%
Balance Sheet & Solvency
Debt to Equity Ratio	0.34	0.61
Dividend Yield	8.00%	4.84%
Historical Growth
3-Year Sales Growth (CAGR)	14.17%	11.41%
Latest Quarter Financial Results
Quarterly Revenue (30 Jun 2026)	₹4,031 Cr	₹15,184 Cr
Quarterly Net Profit	₹568 Cr	₹2,895 Cr

Financial Metric

MANKIND

SUNPHARMA

Valuation Multiples

Market Capitalization

₹94,174 Cr

₹4,41,478 Cr

Price to Earnings (P/E)

50.58

36.07

Price to Book (P/B)

5.74

19.73

Profitability & Capital Efficiency

Return on Capital Employed (ROCE)

15.58%

22.11%

Return on Equity (ROE)

13.97%

12.96%

Operating Profit Margin (OPM)

21.31%

27.39%

Net Profit Margin (NPM)

17.59%

12.40%

Balance Sheet & Solvency

Debt to Equity Ratio

0.34

0.61

Dividend Yield

8.00%

4.84%

Historical Growth

3-Year Sales Growth (CAGR)

14.17%

11.41%

Latest Quarter Financial Results

Quarterly Revenue (30 Jun 2026)

₹4,031 Cr

₹15,184 Cr

Quarterly Net Profit

₹568 Cr

₹2,895 Cr